Global Genitourinary Drugs Market, By Disease (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Kidney/Renal Cancer, Genitourinary Cancer), Products (Sex Hormones, Urologicals, Genitourinary Anti-Infectives, Gynaecologicals)
Market Analysis: Global Genitourinary Drugs Market
The Global Genitourinary Drugs Market is expected to rise from its initial estimated value of USD 31.18 billion in 2018 to an estimated value of USD 40.74 billion by 2026 registering a CAGR of 3.4% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising number of pipeline drugs and prevalence of genitourinary disorders.
Get Inquire Before Buying @
Market Definition: Global Genitourinary Drugs Market
Genitourinary drugs are applicable in the treatment of various cancers, related to the bladder, kidney, urethra and ureters. Various steroids and immunosuppressants are available which leads the side effects in the treatment of related indications. Various biologics products have been developed to treat the infections of genitourinary with less side effects or no side effect such as darifenacin, fesoterodine, VESIcare, tolterodine and many more. Various genitourinary disorders such as urinary tract infections, polycystic kidney disease, glomerulonephritis, prostate cancer and others enhancing the utilization of genitourinary drugs for the treatment of patients.
- Increasing incidences of urinary diseases and related illness that are sexually transmitted.
- Growing concerns about urinary incontinence and impotency
- Increasing advent of counterfeit drugs
- Lack of compliance to medication
Get Detailed For ToC @
Segmentation: Global Genitourinary Drugs Market
- By Disease
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Cervical Cancer
- Kidney/Renal Cancer
- Genitourinary Cancer
- By Products
- Sex Hormones
- Genitourinary Anti-Infective
Key Developments in the Market:
In September 2018, TherapeuticsMD, Inc. announced the commercial availability of the Imvexxy 4 mcg in U.S. for the treatment of dyspareunia.
In May 2016, Genentech, Inc. announced the FDA approval of its product Atezolizumab which is a anti–PD-L1 cancer immunotherapy and used for the patients with the urothelial carcinoma.
Competitive Analysis: Global Genitourinary Drugs Market
The global genitourinary drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of genitourinary drugs market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research